PO.TB05.03 · 肿瘤生物学
儿童癌症幸存者中饮食质量与治疗相关心脏毒性的DNA甲基化特征
DNA methylation signatures of diet quality and treatment-related cardiotoxicity in childhood cancer survivors
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:儿童癌症幸存者由于癌症治疗暴露而面临心脏代谢危险因素(CMRF)和心血管疾病(CVD)风险增加。饮食质量的DNA甲基化(DNAm)特征能否弥补这些风险尚不清楚。
方法:我们在来自St. Jude终生队列(St. Jude Lifetime Cohort)的2,191名儿童癌症成年幸存者和283名社区对照者中,研究了饮食质量的血液DNAm特征及其与CMRF/CVD的关联。饮食质量分别采用健康饮食指数(HEI)-2015和替代地中海饮食评分(aMED)进行评估。使用Illumina EPIC BeadChip V1对全基因组DNAm进行分析。我们识别了饮食质量相关DNAm特征在血液中的差异甲基化位点(DMP)、基因(DMG)和区域(DMR),并由此进一步推导出基于DNAm的健康饮食评分(DNAmDiet)。多变量逻辑回归检验了DNAmDiet与七种结局之间的关联:糖代谢异常、高血压、高甘油三酯血症、高胆固醇血症、肥胖、心肌病和心肌梗死。我们还比较了饮食相关与治疗相关的甲基化效应,重点关注健康饮食相关甲基化变化方向与治疗诱导改变方向相反的CpG位点,提示对治疗相关DNAm改变的潜在弥补作用。
结果:我们识别出29个DMP、113个DMR和53个DMG与HEI-2015显著相关,9个DMP、16个DMR和16个DMG与aMED相关(DMP的P<9×10⁻⁸;DMR或DMG的FDR<0.05)。饮食相关的DNAm特征映射到关键基因,包括AHRR、CPOX、CLDND1、GPR15、LY9和MAP4K4,其中许多参与免疫调节、细胞信号传导和营养感应,提示健康饮食可能影响免疫和代谢通路的表观遗传调控。基于aMED特征的DNAmDiet评分与较低的心肌病风险(比值比[OR]=0.76;95% CI,0.65-0.92)、高胆固醇血症风险(OR=0.65;95% CI,0.50-0.84)和高甘油三酯血症风险(OR=0.78;95% CI,0.63-0.97)相关。饮食相关DMP的效应量在幸存者中平均比社区对照者大一倍(|betasurvivor|/|betacontrol|=2.02;P<0.001),尽管两个人群之间存在强相关性(r=0.85;P<0.001)。我们发现,高达87.5%的治疗相关DMP与HEI-2015或aMED评分呈相反关联,其中高达8.9%达到统计学显著性。
结论:健康饮食的DNAm特征与特定心脏代谢和心血管结局的较低风险相关。重要的是,健康饮食相关的DNAm变化与治疗诱导的DNAm改变方向相反,提示通过饮食干预实现表观遗传恢复的潜力。
查看英文原文 English abstract
Background: Childhood cancer survivors are at increased risk of cardiometabolic risk factors (CMRF) and cardiovascular disease (CVD) due to cancer treatment exposures. Whether DNA methylation (DNAm) signature of diet quality can remediate these risks remains unclear.
Methods: We examined blood DNAm signatures of diet quality and their associations with CMRF/CVD among 2,191 adult survivors of childhood cancer and 283 community controls from the St. Jude Lifetime Cohort. Diet quality was assessed using the Healthy Eating Index (HEI)-2015 and alternate Mediterranean Diet Score (aMED), respectively. Genome-wide DNAm was profiled using the Illumina EPIC BeadChip V1. We identified differentially methylated positions (DMPs), genes (DMGs) and regions (DMRs) for diet quality-associated DNAm signatures in blood, from which DNAm-based scores for a healthy diet (DNAmDiet) were further derived. Multivariable logistic regression examined associations between DNAmDiet and seven outcomes: abnormal glucose metabolism, hypertension, hypertriglyceridemia, hypercholesterolemia, obesity, cardiomyopathy, and myocardial infarction. We also compared diet- and treatment-related methylation effects, focusing on CpGs where healthy diet-associated methylation changes occurred in the opposite direction of treatment-induced alterations, suggesting potential remediation of treatment-related DNAm alterations.
Results: We identified 29 DMPs, 113 DMRs, and 53 DMGs significantly associated with HEI-2015, and 9 DMPs, 16 DMRs, and 16 DMGs associated with aMED (P<9×10⁻⁸ for DMPs; FDR<0.05 for DMRs or DMGs). Diet-associated DNAm signatures mapped to key genes including AHRR, CPOX, CLDND1, GPR15, LY9, and MAP4K4, many of which are involved in immune regulation, cellular signaling, nutrient-sensing, suggesting that healthy diet may influence epigenetic regulation of immune and metabolic pathways. A DNAmDiet score based on aMED signatures was associated with lower risk of cardiomyopathy (Odds Ratio [OR]=0.76; 95% CI, 0.65-0.92), hypercholesterolemia (OR=0.65; 95% CI, 0.50-0.84), and hypertriglyceridemia (OR=0.78; 95% CI, 0.63-0.97). Effect sizes for diet-associated DMPs were, on average, twice as large in survivors as in community controls (|betasurvivor|/|betacontrol|=2.02; P<0.001), despite strong correlations between populations (r=0.85; P<0.001). We found that up to 87.5% of treatment-associated DMPs showed opposite associations with HEI-2015 or aMED scores, with up to 8.9% reaching statistical significance.
Conclusions: DNAm signatures of healthy diet were associated with lower risks of specific cardiometabolic and cardiovascular outcomes. Importantly, healthy diet-related DNAm changes were in the opposite direction of treatment-induced DNAm alterations, suggesting potential for epigenetic recovery through dietary interventions.
利益披露 Disclosure
Y. Kim, None..
X. Meng, None..
K. Oh, None..
T. Lan, None..
T. Eulalio, None..
H. L. Mulder, None..
J. B. Easton, None..
J. Zhang, None..
E. Walker, None..
G. A. Neale, None..
D. Srivastava, None..
M. Ni, None..
S. Dixon, None..
M. M. Hudson, None..
Y. Park, None..
Z. Wang, None.